Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

International Journal of Stroke

Volumn 11, Issue 6, 2016, Pages 618-625

  Induruwa, Isuru ^a   Jung, Stephanie M ^b   Warburton, Elizabeth A ^a  

^a Department of Clinical Neurosciences ^*  (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

antiplatelets; glycoprotein VI; platelets; Stroke

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; COLLAGEN; GLYCOPROTEIN VI; LOSARTAN; TICAGRELOR; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; PLATELET MEMBRANE GLYCOPROTEIN VI;

ACUTE CORONARY SYNDROME; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; BRAIN ISCHEMIA; DRUG MECHANISM; DRUG TARGETING; HEMOSTASIS; HUMAN; HYPERTENSION; LACUNAR STROKE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; TRANSIENT ISCHEMIC ATTACK; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; STROKE; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; BRAIN ISCHEMIA; COLLAGEN; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; STROKE;

EID: 84979911429     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1177/1747493016654532     Document Type: Review

References (58)

1. A.G.ThriftD.A.CadilhacT.Thayabaranathan. Global stroke statistics. Int J Stroke2014; 9: 6–18.
2. H.AdamsB.BendixenL.Kappelle. Classification of subtype of acute ischemic stroke. Stroke1993; 23: 35–41.
3. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996; 348: 1329–1339.
4. H.-C.DienerJ.BogousslavskyL.M.Brass. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet2004; 364: 331–337.
5. S.P.JacksonW.S.NesbittS.Kulkarni. Signaling events underlying thrombus formation. J Thromb Haemost2003; 1: 1602–1612.
6. K.KoziakJ.SévignyS.C.RobsonJ.B.SiegelE.Kaczmarek. Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. Thromb Haemost1999; 82: 1538–1544.
7. R.W.FarndaleP.R.SiljanderD.J.OnleyP.SundaresanC.G.KnightM.J.Barnes. Collagen-platelet interactions: Recognition and signalling. Biochem Soc Symp2003; 94: 81–94.
8. 3 activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol2004; 24: 1727–1733.
9. R.T.DorsamS.P.Kunapuli. Central role of the P2Y 12 receptor in platelet activation. J Clin Invest2004; 113: 340–345.
10. J.M.ClemetsonJ.PolgarE.MagnenatT.N.WellsK.J.Clemetson. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem1999; 274: 29019–29024.
11. M.MoroiS.M.Jung. Platelet glycoprotein VI: Its structure and function. Thromb Res2004; 114: 221–233.
12. A.Michelson. Platelets, London: Elsevier/Academic Press, 2013, pp. 215–222.
13. Y.MiuraT.TakahashiS.M.JungM.Moroi. Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen: A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen. J Biol Chem2002; 277: 46197–46204.
14. B.NieswandtW.BergmeierV.SchulteK.RackebrandtJ.E.GessnerH.Zirngibl. Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRγ chain. J Biol Chem2000; 275: 23998–24002.
15. O.BerlangaT.Bori-SanzJ.R.James. Glycoprotein VI oligomerization in cell lines and platelets. J Thromb Haemost2007; 5: 1026–1033.
16. S.M.JungK.TsujiM.Moroi. Glycoprotein (GP) VI dimer as a major collagen-binding site of native platelets: Direct evidence obtained with dimeric GPVI-specific Fabs. J Thromb Haemost2009; 7: 1347–1355.
17. S.M.JungM.MoroiK.Soejima. Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood. J Biol Chem2012; 287: 30000–30013.
18. L.F.MortonP.G.HargreavesR.W.FarndaleR.D.YoungM.J.Barnes. Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: Collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity. Biochem J1995; 306: 337–344.
19. P.SmethurstD.J.OnleyG.E.Jarvis. Structural basis for the platelet-collagen interaction: The smallest motif within collagen that recognizes and activates platelet Glycoprotein VI contains two glycine-proline-hydroxyproline triplets. J Biol Chem2007; 282: 1296–1304.
20. K.HoriiM.L.KahnA.B.Herr. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood2006; 108: 936–942.
21. S.LoyauB.DumontV.Ollivier. Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity. Arterioscler Thromb Vasc Biol2012; 32: 778–785.
22. W.BergmeierT.RabieA.Strehl. GPVI down-regulation in murine platelets through metalloproteinase-dependent shedding. J Thromb Haemost2004; 91: 951–958.
23. E.E.GardinerD.KarunakaranY.ShenJ.F.ArthurR.K.AndrewsM.C.Berndt. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost2007; 5: 1530–1537.
24. M.Al-TamimiF.T.MuJ.F.Arthur. Anti-glycoprotein VI monoclonal antibodies directly aggregate platelets independently of FcgammaRIIa and induce GPVI ectodomain shedding. Platelets2009; 20: 75–82.
25. M.BenderS.HofmannD.Stegner. Differentially regulated GPVI ectodomain shedding by multiple platelete xpressed proteinases. Blood2010; 116: 3347–3355.
26. P.J.Newman. GPVI and the not so eager cleaver. Blood2010; 116: 3124–3126.
27. M.MoroiS.M.JungM.OkumaK.Shinmyozu. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest1989; 84: 1440–1445.
28. B.B.NieswandtV.SchulteW.Bergmeier. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med2001; 193: 459–469.
29. A.MisraM.Dikshit. Platelets and arterial thrombosis: Evolving role of platelet GPVI as an antithrombotic drug target. Proc Indian Natl Sci Acad2014; 80: 289.
30. B.BigalkeK.StellosT.Geisler. Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke. Eur J Neurol2010; 17: 111–117.
31. M.Al-TamimiE.E.GardinerJ.Y.Thom. Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke2011; 42: 498–500.
32. Behrouz R, Malek AR and Torbey MT. Small vessel cerebrovascular disease: The past, present, and future. Stroke Res Treat 2012; 2012
33. A.HassanB.J.HuntM.O'Sullivan. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain2003; 126: 424–432.
34. I.L.H.KnottnerusJ.W.P.Govers-RiemslagK.Hamulyak. Endothelial activation in lacunar stroke subtypes. Stroke2010; 41: 1617–1622.
35. M.van OijenJ.C.WittemanA.HofmanP.J.KoudstaalM.M.B.Breteler. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke2005; 36: 2637–2641.
36. O.M.AlshehriC.E.HughesS.Montague. Fibrin activates GPVI in human and mouse platelets. Blood2015; 126: 1601–1608.
37. E.Mammadova-BachV.OllivierS.Loyau. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood2015; 26: 683–689.
38. B.NieswandtI.PleinesM.Bender. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost2011; 9: 92–104.
39. J.P.Maffrand. The story of clopidogrel and its predecessor, ticlopidine: Could these major antiplatelet and antithrombotic drugs be discovered and developed today?Comptes Rendus Chim2012; 15: 737–743.
40. C.M.GeeganageH.-C.DienerA.Algra. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: Systematic review and meta-analysis of randomized controlled trials. Stroke2012; 43: 1058–1066.
41. H.P.AdamsM.B.EffronJ.Torner. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke2008; 39: 87–99.
42. E.E.Gardiner. Targeting GPVI as a novel antithrombotic strategy. J Blood Med2014; 5: 59–68.
43. C.KleinschnitzM.PozgajovaM.PhamM.BendszusB.NieswandtG.Stoll. Targeting platelets in acute experimental stroke: Impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation2007; 115: 2323–2330.
44. S.MassbergM.GawazS.Gruner. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med2002; 197: 41–49.
45. S.MassbergI.KonradA.Bültmann. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J2004; 18: 397–399.
46. Y.MatsumotoH.TakizawaX.Gong. Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization. Thromb Res2007; 119: 319–329.
47. H.LiS.LockyerA.Concepcion. The fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. Arterioscler Thromb Vasc Biol2007; 27: 1199–1205.
48. C.LecutL.A.FeeneyG.Kingsbury. Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. J Thromb Haemost2003; 1: 2653–2662.
49. P.KraftM.K.SchuhmannF.Fluri. Efficacy and safety of platelet glycoprotein receptor blockade in aged and comorbid mice with acute experimental stroke. Stroke2015; 46: 3502–3506.
50. B.BoylanH.ChenV.Rathore. Anti-GPVI-associated ITP: An acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRy-chain complex from the human platelet surface. Blood2004; 104: 1350–1355.
51. M.UngererK.RosportA.Bültmann. Novel antiplatelet drug Revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation2011; 123: 1891–1899.
52. S.GoebelZ.LiJ.Vogelmann. The GPVI-Fc fusion protein revacept improves cerebral infarct volume and functional outcome in stroke. PLoS One2013; 8: e66960.
53. A.BültmannZ.LiS.Wagner. Impact of glycoprotein VI and platelet adhesion on atherosclerosis–a possible role of fibronectin. J Mol Cell Cardiol2010; 49: 532–542.
54. Poppert H. Revacept in symptomatic carotid stenosis (Revacept/CS/02). http://clinicaltrials.gov/show/NCT01645306. NLM Identifier: NCT01645306 (accessed 31 May 2015)
55. C.KrämerJ.SunkomatJ.Witte. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: Role of the active metabolite EXP3179. Circ Res2002; 90: 770–776.
56. C.GrothusenS.UmbreenI.Konrad. EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: Potential impact on atherothrombosis. Arterioscler Thromb Vasc Biol2007; 27: 1184–1190.
57. K.OnoH.UedaY.Yoshizawa. Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI. J Med Chem2010; 53: 2087–2093.
58. P.SmethurstL.Joutsi-KorhonenM.N.O'Connor. Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood2004; 103: 903–911.